Immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant—erased all ...
The companies have teamed up to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell ...
Treatment with an experimental CAR-T therapy for multiple myeloma from Arcellx and Gilead Sciences resulted in zero cases of delayed neurotoxicity, including Parkinsonian symptoms and cranial ...